Positive News SentimentPositive NewsNASDAQ:EPRX Eupraxia Pharmaceuticals (EPRX) Stock Price, News & Analysis $3.86 -0.01 (-0.26%) Closing price 03:59 PM EasternExtended Trading$3.84 -0.02 (-0.52%) As of 05:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Eupraxia Pharmaceuticals Stock (NASDAQ:EPRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get EPRX alerts:Sign Up Key Stats Today's Range$3.85▼$3.9250-Day Range$2.93▼$4.1052-Week Range$2.20▼$4.48Volume34,225 shsAverage Volume12,893 shsMarket Capitalization$138.38 millionP/E RatioN/ADividend YieldN/APrice Target$10.50Consensus RatingBuy Company OverviewEupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.Read More… Eupraxia Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks59th Percentile Overall ScoreEPRX MarketRank™: Eupraxia Pharmaceuticals scored higher than 59% of companies evaluated by MarketBeat, and ranked 623rd out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus RatingEupraxia Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEupraxia Pharmaceuticals has received no research coverage in the past 90 days.Read more about Eupraxia Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Eupraxia Pharmaceuticals are expected to grow in the coming year, from ($0.67) to ($0.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Eupraxia Pharmaceuticals is -5.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Eupraxia Pharmaceuticals is -5.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEupraxia Pharmaceuticals has a P/B Ratio of 128.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Eupraxia Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.50% of the float of Eupraxia Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEupraxia Pharmaceuticals has a short interest ratio ("days to cover") of 8.1.Change versus previous monthShort interest in Eupraxia Pharmaceuticals has recently decreased by 2.59%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEupraxia Pharmaceuticals does not currently pay a dividend.Dividend GrowthEupraxia Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.50% of the float of Eupraxia Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEupraxia Pharmaceuticals has a short interest ratio ("days to cover") of 8.1.Change versus previous monthShort interest in Eupraxia Pharmaceuticals has recently decreased by 2.59%, indicating that investor sentiment is improving. News and Social Media3.3 / 5News SentimentN/A News SentimentEupraxia Pharmaceuticals has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Eupraxia Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for EPRX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added Eupraxia Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Eupraxia Pharmaceuticals insiders have not sold or bought any company stock.Read more about Eupraxia Pharmaceuticals' insider trading history. Receive EPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eupraxia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address EPRX Stock News HeadlinesEupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 2025May 7, 2025 | financialpost.comEupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 2025May 7, 2025 | globenewswire.comTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new blockchain development…May 27, 2025 | Crypto 101 Media (Ad)Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial ResultsMay 7, 2025 | finanznachrichten.deEupraxia Pharmaceuticals Reports First Quarter 2025 Financial ResultsMay 6, 2025 | globenewswire.comEupraxia Pharmaceuticals to Present at Investor and Scientific Conferences in April and MayApril 24, 2025 | financialpost.comEupraxia Pharmaceuticals to Present at Investor and Scientific Conferences in April and MayApril 24, 2025 | financialpost.comEupraxia Pharmaceuticals to Present at Investor and Scientific Conferences in April and MayApril 24, 2025 | globenewswire.comSee More Headlines EPRX Stock Analysis - Frequently Asked Questions How have EPRX shares performed this year? Eupraxia Pharmaceuticals' stock was trading at $3.17 at the beginning of the year. Since then, EPRX stock has increased by 21.8% and is now trading at $3.86. View the best growth stocks for 2025 here. How were Eupraxia Pharmaceuticals' earnings last quarter? Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) announced its earnings results on Tuesday, May, 6th. The company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by $0.02. Who are Eupraxia Pharmaceuticals' major shareholders? Eupraxia Pharmaceuticals' top institutional investors include Scotia Capital Inc. (4.33%) and Royal Bank of Canada (0.96%). How do I buy shares of Eupraxia Pharmaceuticals? Shares of EPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Eupraxia Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Eupraxia Pharmaceuticals investors own include Aeterna Zentaris (AEZS), BlackBerry (BB), Bausch Health Companies (BHC), Bitfarms (BITF), Ballard Power Systems (BLDP), Cardiol Therapeutics (CRDL) and Fury Gold Mines (FURY). Company Calendar Last Earnings5/06/2025Today5/27/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:EPRX Previous SymbolNASDAQ:EPRX CIK1581178 Webwww.eupraxiapharma.com Phone250-590-3968FaxN/AEmployees29Year FoundedN/APrice Target and Rating Average Stock Price Target$10.50 High Stock Price Target$12.00 Low Stock Price Target$9.00 Potential Upside/Downside+172.0%Consensus RatingBuy Rating Score (0-4)3.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$28.22 million Net MarginsN/A Pretax MarginN/A Return on Equity-219.64% Return on Assets-96.00% Debt Debt-to-Equity RatioN/A Current Ratio4.17 Quick Ratio4.17 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.03 per share Price / Book128.67Miscellaneous Outstanding Shares35,849,000Free FloatN/AMarket Cap$138.38 million OptionableN/A BetaN/A Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:EPRX) was last updated on 5/27/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eupraxia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eupraxia Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.